EMERGENT BIOSOLUTIONS INC. Proceeds from Long-term Lines of Credit
EMERGENT BIOSOLUTIONS INC. (EBS) reported Proceeds from Long-term Lines of Credit of $0 for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-27.
Financial Statements › Cash Flow › Financing Activities
us-gaap:ProceedsFromLongTermLinesOfCredit · last filed 2026-02-27
- EMERGENT BIOSOLUTIONS INC. proceeds from long-term lines of credit for the quarter ending 2025-12-31 was $0.00.
- EMERGENT BIOSOLUTIONS INC. proceeds from long-term lines of credit for the quarter ending 2025-09-30 was $0.00.
- EMERGENT BIOSOLUTIONS INC. proceeds from long-term lines of credit for the quarter ending 2025-06-30 was $0.00, a 100.00% decline year-over-year.
- EMERGENT BIOSOLUTIONS INC. proceeds from long-term lines of credit for the quarter ending 2025-03-31 was $0.00, a 100.00% decline year-over-year.
- EMERGENT BIOSOLUTIONS INC. proceeds from long-term lines of credit for fiscal 2025 was $0.00, a 100.00% decline from fiscal 2024.
- EMERGENT BIOSOLUTIONS INC. proceeds from long-term lines of credit for fiscal 2024 was $65.00M, a 225.00% increase from fiscal 2023.
- EMERGENT BIOSOLUTIONS INC. proceeds from long-term lines of credit for fiscal 2023 was $20.00M, a 96.66% decline from fiscal 2022.
- EMERGENT BIOSOLUTIONS INC. proceeds from long-term lines of credit for fiscal 2022 was $598.00M.
| Period end | Proceeds from Long-term Lines of Credit 3 month | Proceeds from Long-term Lines of Credit 6 month | Proceeds from Long-term Lines of Credit 9 month | Proceeds from Long-term Lines of Credit 12 month |
|---|---|---|---|---|
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27 | $0.00 derived: sum of 2 quarters · filed 2026-02-27 | $0.00 derived: sum of 3 quarters · filed 2026-02-27 | $0.00 10-K · filed 2026-02-27 |
| 2025-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-30 | $0.00 derived: sum of 2 quarters · filed 2025-10-30 | $0.00 10-Q · filed 2025-10-30 | $0.00 derived: sum of 4 quarters · filed 2026-02-27 |
| 2025-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | $0.00 10-Q · filed 2025-08-07 | $0.00 derived: sum of 3 quarters · filed 2026-02-27 | $0.00 derived: sum of 4 quarters · filed 2026-02-27 |
| 2025-03-31 | $0.00 10-Q · filed 2025-05-08 | $0.00 derived: sum of 2 quarters · filed 2026-02-27 | $0.00 derived: sum of 3 quarters · filed 2026-02-27 | $15.00M derived: sum of 4 quarters · filed 2026-02-27 |
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27 | $0.00 derived: sum of 2 quarters · filed 2026-02-27 | $15.00M derived: sum of 3 quarters · filed 2026-02-27 | $65.00M 10-K · filed 2026-02-27 |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-30 | $15.00M derived: sum of 2 quarters · filed 2025-10-30 | $65.00M 10-Q · filed 2025-10-30 | $85.00M derived: sum of 4 quarters · filed 2026-02-27 |
| 2024-06-30 | $15.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | $65.00M 10-Q · filed 2025-08-07 | $85.00M derived: sum of 3 quarters · filed 2026-02-27 | $85.00M derived: sum of 4 quarters · filed 2026-02-27 |
| 2024-03-31 | $50.00M 10-Q · filed 2025-05-08 | $70.00M derived: sum of 2 quarters · filed 2026-02-27 | $70.00M derived: sum of 3 quarters · filed 2026-02-27 | $70.00M derived: sum of 4 quarters · filed 2026-02-27 |
| 2023-12-31 | $20.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27 | $20.00M derived: sum of 2 quarters · filed 2026-02-27 | $20.00M derived: sum of 3 quarters · filed 2026-02-27 | $20.00M 10-K · filed 2026-02-27 |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | $0.00 derived: sum of 2 quarters · filed 2024-11-07 | $0.00 10-Q · filed 2024-11-07 | $360.00M derived: sum of 4 quarters · filed 2025-03-04 |
| 2023-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-07 | $0.00 10-Q · filed 2024-08-07 | $360.00M derived: sum of 3 quarters · filed 2025-03-04 | |
| 2023-03-31 | $0.00 10-Q · filed 2024-05-02 | $360.00M derived: sum of 2 quarters · filed 2025-03-04 | ||
| 2022-12-31 | $360.00M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-04 | $598.00M 10-K · filed 2025-03-04 | ||
| 2022-09-30 | $238.00M 10-Q · filed 2023-12-11 | |||
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-08 | $0.00 10-K · filed 2024-03-08 | ||
| 2021-09-30 | $0.00 10-Q · filed 2022-11-09 | |||
| 2020-12-31 | $0.00 10-K/A · filed 2023-12-11 | |||
| 2019-12-31 | $130.00M 10-K · filed 2022-02-25 | |||
| 2018-12-31 | $348.00M 10-K · filed 2021-02-19 | |||
| 2017-12-31 | $0.00 10-K · filed 2020-02-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ENANTA PHARMACEUTICALS INC (ENTA) | United States | $0.349B | -6.72 |
| Larimar Therapeutics, Inc. (LRMR) | United States | $0.344B | -1.83 |
| Vogenx, Inc. (VOGX) | United States | $0.355B | |
| Benitec Biopharma Inc. (BNTC) | United States | $0.337B | -10.08 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Rezolute, Inc. (RZLT) | United States | $0.382B | -6.45 |